Board Member
Tapestry, Inc. (TPR)Equibles does not estimate personal net worth.
Get an email with a short summary when Bristol Myers Squibb Co publishes a filing, an earnings call transcript or a press release.
Get BMY alertsDavid Elkins is recorded as CFO at Bristol Myers Squibb Co (BMY) and Board Member at Tapestry, Inc. (TPR) since January 1, 2024. The newest filing on record that lists David Elkins as CFO at Bristol Myers Squibb Co (BMY) is dated March 25, 2026. The newest filing on record that lists David Elkins as Board Member at Tapestry, Inc. (TPR) is dated September 25, 2026. Tapestry, Inc. reported in an 8-K filed February 29, 2024 that David Elkins was appointed director, effective February 29, 2024. The proxy statement of Bristol Myers Squibb Co reports total compensation of $9,177,590 for David Elkins in fiscal 2025, including a base salary of $1,140,442. Disclosed compensation is on record for 4 fiscal years. David Elkins has spoken on 27 earnings calls across 1 company, most recently for Bristol Myers Squibb Co on October 29, 2026. Bristol Myers Squibb Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Tapestry, Inc. is classified in the Luxury Goods industry within the Consumer Cyclical sector. Other leadership on record at Bristol Myers Squibb Co includes Christopher Boerner (CEO, COO and Board Member), Christopher Boerner, Ph.D. (CEO, COO and Board Member), Sandra Leung (General Counsel) and 5 others.
“the Board of Directors (the "Board") of Tapestry, Inc. ("Tapestry" or the "Company") increased the size of the Board from nine to eleven members and elected each of Kevin Hourican and David Elkins as a director of the Company, effective as of February 29, 2024.”
“Our third quarter results reflect continued strong execution across our growth portfolio and continued strength from Eloquist. We remain focused on financial discipline, balancing investments in our growth drivers with continued productivity improvements.”
“We delivered another strong quarter, with the results continuing to highlight the underlying strength of our growth portfolio, comprised of many products that are early in their life cycles.”
“Our performance in 2026 is off to a strong start as highlighted by our first quarter results. We delivered solid R&D, commercial, and financial performance while continuing to manage our cost structure.”
“What I'd also say is it's also enabled us to reinvest in growth drivers. Some of the investments we did last year with as well as but also with a couple of the deals that we did with Orbital Therapeutics, as well as we'll be analyzing those costs here in 26.”
“I'm pleased to report another strong quarter of execution. The growth portfolio continues to perform well, and we continue to maintain cost discipline. Now turning to the third quarter sales performance on Slide 7.”
2024-01-01–present
Last confirmed September 25, 2026
Start not stated–present
Last confirmed March 25, 2026
Drug Manufacturers - General · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bristol Myers Squibb Co (BMY) | EVP and Chief Financial Officer | $1,140,442 | $9,177,590 |
| 2024 | Bristol Myers Squibb Co (BMY) | EVP and Chief Financial Officer | $1,115,000 | $8,707,571 |
| 2023 | Bristol Myers Squibb Co (BMY) | EVP and Chief Financial Officer | $1,106,176 | $7,166,300 |
| 2022 | Bristol Myers Squibb Co (BMY) | EVP and Chief Financial Officer | $1,073,859 | $7,647,290 |
